Almirall's 16th Skin Academy Brings Together Leading Experts to Advance Skin Science and Treatment Options in Medical Dermatology
Almirall’s 16th Skin Academy is a unique opportunity for collaboration in medical dermatology as it brings together leading experts from across the globe to advance science and innovative approaches for the treatment of skin diseases.The conference focuses on the latest advancements in medical dermatology, including the holistic and personalized treatment of atopic dermatitis and psoriasis.The comprehensive program covers a broad range of skin diseases such as actinic keratosis, androgenetic alopecia, onychomycosis and chronic spontaneous urticaria - advancing the understanding of these diseases and treatment options to support better patient outcomes.
Almirall, a global pharmaceutical company dedicated to medical dermatology hosts the 16th edition of Skin Academy, a premier conference for healthcare professionals in the field of dermatology. This year's event features a comprehensive program aimed at sharing state-of-the-art scientific knowledge on skin diseases, their treatment, and clinical best practice.
The Skin Academy is a unique opportunity for collaboration, bringing together a broad range of leading experts and clinicians from across the globe to create a network of peers that discuss and learn together to advance the treatment of skin diseases. The event will foster collaboration and co-creation of innovative approaches and solutions to better respond to the unmet needs of the millions of people living with dermatological conditions.
Prof. Dr. Ulrich Mrowietz, from the Psoriasis Center at the University Medical Center Schleswig-Holstein, Campus Kielin Germany said: "deep collaboration across experts is essential for advancing medical dermatology and providing better treatment outcomes for patients. Almirall’s Skin Academy provides a unique platform for practitioners to explore latest scientific advances, clinical practice and discuss a broad range of skin diseases, with an emphasis on holistic, personalized patient care and wellbeing."
The Chief Medical Officer of Almirall, Dr. Volker Koscielny, said: "this is the 16th edition of the Skin Academy, and we are proud to continue to provide a leading platform for exchange and advancement in medical dermatology. Partnering with the dermatology community across Europe is based on our unique focus on medical dermatology and supported by our R&D capabilities as well as our strong collaborations. Skin Academy fosters collaboration and co-creation of innovative approaches and solutions that help the medical dermatology community to better respond to the unmet needs of millions of people living with these conditions."
About Almirall’s Skin Academy
The Skin Academy, initiated and sponsored by Almirall, has become a cornerstone event for healthcare professionals in medical dermatology. Over the years, it has evolved into a key platform for sharing state-of-the-art scientific knowledge and clinical best practices in a wide range of skin diseases that affect millions of people. The event encourages collaboration and the development of new methods and solutions, aiming at addressing the unmet needs of patients and the medical dermatology community. The 16th edition continues this focus and Almirall’s commitment to educational advancement, bringing together over 800 participants, led by international experts, with common interests to create a network to discuss, educate, and learn to advance knowledge in medical dermatology.
About atopic dermatitis
As a highly prevalent and debilitating condition, atopic dermatitis will be a central focus at the conference, with experts offering new insights into its pathophysiology, the role of IL-13, and the importance of advanced treatment protocols. In addition, the discussion will include a comprehensive analysis of efficacy and safety of leading treatments over time, as well as real-world evidence from clinical practice. Another key topic is the dermatologist-patient relationship, which is crucial for treatment success, especially based on the role of shared decision-making in treatment planning.
About psoriasis
Psoriasis will be another focus area for the 16th Skin Academy, and will be addressed in a range of sessions specifically dedicated to biologic treatments. The speakers will address unmet medical needs, the importance of individualized treatment for long-term disease control and share real world evidence showing the effectiveness and safety of targeted IL-23 inhibition, as well as highlighting the importance of striving for patient wellbeing as treatment outcome. Moreover, as difficult-to-treat areas of the skin remain of special importance for patients suffering from psoriasis, current treatment challenges and approaches to address these will be discussed, including advancements in topical treatments and new efficacy data with IL-23 inhibition in psoriasis of the scalp, which affects 40-90% of patients with psoriasis1234.
About Actinic Keratosis
The conference will address the crucial relationship between patients and their physicians, which is essential for treatment success and patient satisfaction, particularly in managing chronic skin diseases. It will highlight the importance of early treatment in actinic keratosis (AK) to prevent its progression to squamous cell carcinoma. Experts will cover advancements in AK treatment, real-world evidence, and the role of patient satisfaction in treatment outcomes.
The conference program further includes topics on other important dermatological conditions, including androgenetic alopecia, onychomycosis, and chronic spontaneous urticaria. The event will also feature poster sessions, clinical case discussions, and Q&A sessions with experts, ensuring an engaging and interactive experience for all participants.
About Almirall
Almirall is a global pharmaceutical company dedicated to medical dermatology. We closely collaborate with leading scientists, healthcare professionals, and patients to deliver our purpose: to transform the patients' world by helping them realize their hopes and dreams for a healthy life. We are at the forefront of science to deliver ground-breaking, differentiated medical dermatology innovations that address patients' needs.
Almirall, founded in 1944 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange (ticker: ALM, total revenue in 2024: €990 MM, over 2000 employees globally). Almirall products help to improve the lives of patients every day and are available in over 100 countries.
For more information, please visit https://www.almirall.com/
1 Augustin M, Sommer R, Kirsten N, et al. Topology of psoriasis in routine care: results from high-resolution analysis of 2009 patients. Br J Dermatol. 2019;181:358-365. |
2 Egeberg A, See K, Garrelts A, et al. Epidemiology of psoriasis in hard-to-treat body locations: data from the Danish skin cohort. BMC Dermatol. 2020;20:3. |
3 Merola JF, Li T, Li WQ, et al. Prevalence of psoriasis phenotypes among men and women in the USA. Clin Exp Dermatol. 2016; 41:486-489. |
4 Sampogna F, Linder D, Piaserico S, et al. Quality of life assessment of patients with scalp dermatitis using the Italian version of the Scalpdex. Acta Derm Venereol. 2014;94: 411-414. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20250320758758/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hoffmann Green Strengthens Its Intellectual Property With European Patent for H-EVA Cement25.3.2025 18:00:00 CET | Press release
Hoffmann Green Cement Technologies (ISIN: FR0013451044, Ticker: ALHGR) (“Hoffmann Green Cement” or the “Company”), an industrial player committed to the decarbonation of the construction sector that designs and markets innovative clinker-free cements, today announces the granting of a European patent for its H-EVA 0% clinker cement. This strategic achievement is in line with Hoffmann Green's dynamic international expansion and marks a new stage in the protection of its intellectual property. After more than 6 years of instruction, the H-EVA patent, validated by the European Patent Office under number EP 18 812 243.6, illustrates the added value of the company's Research & Development model, reinforcing its advanced positioning in the decarbonized cement market. Main characteristics of the H-EVA breakthrough technology: Alkali-ettringitic cement; Cement without clinker (0%); Cement in the form of a powder that can be stored in a silo, just like traditional cement; Perfect compatibility
HyperLight Launches 110GHz Intensity Modulator with Record low Vπ, Leveraging Its TFLN Chiplet™ Platform25.3.2025 17:00:00 CET | Press release
HyperLight, creator of the TFLN Chiplet™ platform, today announced the launch of its groundbreaking 110 GHz Low Vπ Intensity Modulator, featuring industry-standard optical fiber and microwave connectors. This industry-first device significantly advances electro-optic modulation capabilities for critical applications, including 400 Gbps-per-lane testing, 100 GHz+ photodiode calibration, high-frequency radio-over-fiber systems, and various other cutting-edge technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250325461709/en/ HyperLight's New 110 GHz Low Vπ Intensity Modulator with Record Low 1.4V Half-Wave Voltage Leveraging HyperLight's proprietary TFLN Chiplet™ platform, this revolutionary modulator achieves an unprecedented half-wave voltage (Vπ) of just 1.4 V with bandwidth performance exceeding 110 GHz—setting a new benchmark in high-bandwidth modulation. Combining ultra-low Vπ with minimal insertion loss and ex
Neural Potential: Mouser Series Explores Brain Computer Interfaces at the Intersection of Technology and the Mind25.3.2025 16:18:00 CET | Press release
Mouser Electronics, Inc., the authorized global distributor with the newest electronic components and industrial automation products, today announced the release of the latest installment of the Empowering Innovation Together(EIT) technology series, which examines the rapidly evolving field of brain-computer interfaces (BCIs). This series takes a deep dive into the engineering challenges and opportunities in the development of mind-controlled systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250325376038/en/ BCIs create direct communication between the brain and external devices, enabling applications like motor function restoration for individuals with paralysis, speech enhancement for those with communication impairments, and even cognitive augmentation. These systems rely on electrode-based neural signal acquisition and advanced signal processing algorithms to translate brain activity into actionable commands. In th
New Milestone as Sweden Enshrines Policy That Can Turn World Smoke-Free25.3.2025 15:57:00 CET | Press release
Sweden has enshrined tobacco harm reduction in public health policy after becoming the first nation to prove it’s the most effective path to a smoke-free future. Thanks to Sweden’s stance on safer nicotine alternatives, just 4.5% of Swedish-born adults now smoke - below the 5% smoke-free threshold. This success has led Parliament to formally adopt harm reduction, reinforcing Sweden’s role as a global leader in public health innovation. Dr. Delon Human, leader of Smoke Free Sweden, says: “Swedes have participated in a long-running harm reduction experiment, providing undeniable proof that replacing smoking with smokeless nicotine dramatically reduces smoking-related disease, disability and premature deaths - a net gain for public health, while reducing expenditure. “With harm reduction now policy in Sweden, every public health decision will reflect this approach. Other countries should adopt Sweden’s model without further delay.” Rather than reducing tobacco use, Sweden now prioritises
Neos Kicks Off Global Indie Game Publishing Business25.3.2025 15:00:00 CET | Press release
-New Label "IndieTech Games" Launched- Neos has launched "IndieTech Games," a label dedicated to publishing high-quality indie games worldwide, including in Japan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250320035646/en/ IndieTechGames Neos entered the game development and publishing business for Nintendo Switch in 2019, starting with the release of "Shin chan: Me and the Professor on Summer Vacation - The Endless Seven-Day Journey" in Japan in 2021. The title later expanded to Asia, Europe, and North America in the following year, and eventually to the rest of the world, achieving cumulative shipments of over 500,000 units. The latest title, "Shin chan: Shiro and the Coal Town," has also been released globally and has been well received, following the success of its predecessor with cumulative shipments exceeding 300,000 units. Through the sales and marketing of our in-house developed titles, we have had more opportu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom